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Abstract
Background: Treatment of severe asthma may include high dose systemic-steroid therapy which is associated with
substantial additional morbidity. This study estimates the additional healthcare costs associated with steroid-
induced morbidity by comparing three patients groups: those with severe asthma, moderate asthma and no
asthma.
Methods: Patients with severe asthma (n = 808, GINA step 5 treatment) were matched by age and gender with
patients with mild/moderate asthma (n = 3,975, GINA step 2 and 3 treatment) and a non-asthma control cohort
(with a diagnosis of rhinitis; n = 2,412) from the Optimum Patient Care Research Database (OPCRD), a nationally
representative primary care database. Prescribed drugs and publicly funded healthcare activity were monetised and
annual costs per patient estimated. Regression analyses were used to estimate the additional healthcare cost
associated with steroid-induced morbidity.
Results: Average healthcare costs per person per year range from £2603 - £4533 for the severe asthma cohort, to
£978 - £2072 for the mild/moderate asthma cohort, to £560 - £1324 for the non-asthma control cohort, depending
on the costing scenario. Differences in induced morbidity costs were evident between patients with asthma
differentiated by steroid exposure. In relation to prescription drugs used to treat steroid-induced co-morbidities,
females with severe asthma and high steroid exposure cost approximately £789 more per year than a
corresponding female with no asthma, while males cost approximately £744 more than their counterparts with no
asthma. Estimates were extrapolated to all healthcare costs.
Conclusions: This study provides the first robust estimates of the additional cost of healthcare related to steroid-
induced morbidity relative to patients with no steroid exposure. The study will help inform use of steroid-sparing
strategies in this patient group.
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Background
Asthma is estimated to affect up to 334 million people
worldwide [1] and presents a substantive burden in
terms of morbidity, mortality and economic costs. Esti-
mates of the economic burden vary but in the United
States (US) and Europe the annual figure is measured in
the billions, both in US Dollars and Euros [2–4].
Patients with Severe Asthma (SA) contribute dispro-
portionately to the overall burden [5, 6]. They have
higher levels of healthcare utilization including unsched-
uled primary care visits and hospital admissions, along
with greater drug therapy consumption and diagnostic
procedures relative to those with mild asthma and non-
asthmatics [7]. While previous research has focused on
ascertaining the burden of disease associated with
asthma and variations across patients with differing dis-
ease severity, an area of increased interest concerns the
cost specifically associated with corticosteroid-induced
morbidity.
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Prolonged exposure to corticosteroids among asthma
patients particularly severe asthmatics, has been impli-
cated in a range of morbidities including hypertension,
diabetes, arthritis and osteopenia [8]. A higher preva-
lence of these and other conditions has been demon-
strated among those with higher exposure to
corticosteroids [9]. It has been shown also that among
those with SA, drug costs are the main driver of total
healthcare costs and costs unrelated to asthma were
higher for patients on maintenance oral corticosteroids
(OCS) [7].
Others have examined differences in the cost of man-
aging specific comorbid conditions between groups with
high (>12 mg/day), moderate (6-12 mg/day) and low
(≤6 mg/day) corticosteroid exposure, (although a non-
exposure control group was not used in this analysis)
[10]. This work has shown that the costs associated with
managing a list of specific conditions related to systemic
corticosteroids is USD $1194 and $5479 higher among
medium and high exposed groups relative to a low ex-
posure group respectively [10].
In this paper we examine differences in healthcare
costs related to corticosteroid exposure between patient
groups with and without asthma (diagnosed with rhin-
itis) as well as differentiated by asthma severity within
the asthma group. We use nationally representative data
from the UK and focus attention on the relationship be-
tween morbidity and corticosteroid exposure to better
understand the impact of systemic corticosteroid expos-
ure on the cost of managing comorbid conditions.
Methods
Cohort definition
Patients with SA (n = 808) requiring regular OCS
(defined as Global Initiative for Asthma (treatment at
GINA) step 5 treatment [10, 11] and ≥4 prescriptions
for OCS in each of two consecutive study years) were
compared with patients with mild/moderate asthma
(n = 3975) and non-asthmatic controls (n = 2412). Data
were obtained from the Optimum Patient Care Research
Database (OPCRD) a large nationally representative pri-
mary care practice database [8]. Subjects were required to
be over 12 years of age and to have at least 2 years of con-
tinuous medical records, so that 24 months of continuous
primary care data were available for analysis. Two control
cohorts were individually matched to the SA cohort for
age, gender and year of birth (due to differing data extrac-
tion dates – data were extracted between 2008 and 2013),
one with mild/moderate asthma (asthma diagnosis, treat-
ment at GINA step 2/3 [11]), the other consisting of non-
asthmatic controls.
Patients were included in the non-asthmatic control
group if they had a rhinitis diagnosis with no asthma
diagnosis/asthma drug prescription and no exposure to
OCS as evidenced by the patterns of service use in
OPCRD. To avoid any risk of non-asthma related
exposure to corticosteroids, subjects with the following
conditions for which systemic corticosteroids may be
prescribed were removed from the data: Crohn’s disease,
ulcerative colitis, autoimmune hepatitis, rheumatoid
arthritis, polymyalgia rheumatic, chronic obstructive pul-
monary disease, bronchiectasis, cystic fibrosis, interstitial
lung disease, tuberculosis. Thus the mild/moderate
asthma group had some OCS exposure and had inhaled
corticosteroid (ICS) exposure. As such the change in co-
hort from non-asthma to mild/moderate asthma to se-
vere asthma represents a change in corticosteroid
exposure from none to low to high exposure. The data
included details of all publicly funded healthcare consul-
tations, including primary and hospital care as well as
details of prescribed therapies/drugs.
Monetising data – healthcare activity
A list of all interactions with health service personnel
(healthcare activities), detailed in Read codes (RC) [12],
were extracted from the database. RC’s are used by clini-
cians to report details on interactions with patients in-
cluding procedures undertaken as well as referrals made;
codes are arranged in a hierarchical fashion, all codes
beginning with three for example denoting Diagnostic
Procedures (see Additional file 1: Table S9); the RC
3361.00 denoting, more specifically, ‘Allergy Testing
Done’. At lower levels of the hierarchy, RC’s may be
elaborated with additional detail entered in records as
free text.
As such, the monetisation required an approach tai-
lored very specifically to this dataset. Full details of this
are available in the supplement but in summary, monet-
isation of interactions involved a series of steps; first, an
algorithm was developed and used to assign a consult-
ation type to each RC. For example, ‘asthma assessment’,
might initially be assigned a General Practice (GP) con-
sultation based on where the procedure was likely to be
undertaken – a GP surgery. Next, algorithm based as-
signments were independently reviewed by two re-
searchers (JS and CON) and based on an examination of
the RC, assignments were confirmed or amended.
Where uncertainty remained as to the appropriate as-
signment, for example where a practice nurse or a GP
could have performed a particular activity, high-low cost
scenarios were developed based on alternative possibil-
ities and used in subsequent sensitivity analyses. Activity
which was documented as occurring outside the GP was
also costed, for example outpatient visits, X-Rays or GP
administration.
Confirmatory analysis of healthcare activity costing
was undertaken on a random sample of 22 study sub-
jects across cohorts in which all levels of the hierarchy
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were used to infer an assignable unit cost. Cost estimates
based on this were compared with those based on the al-
gorithm using a correlation coefficient.
Activity was monetised by reference to Personal Social
Services Research Unit (PSSRU) 2013 unit cost estimates
[13]. The PSSRU presents median and inter-quartile
range (IQR) estimates for consultation types. This range
was used as part of sensitivity analyses undertaken.
Where IQR’s were not provided, a range of costs were
calculated based on the value reported in the PSSRU
and using a standard gamma distribution (θ ∼ gamma
(α,β)), commonly used for cost data [14], with mean and
variance as parameters of 10,000 simulated observations
for sensitivity analyses.
This resulted in six potential scenarios for the monet-
isation of each healthcare activity; the median, the upper
and lower quartile PSSRU (or gamma distribution) esti-
mates for the high and low cost scenarios where uncer-
tainty existed as to the appropriate activity to relate to a
given RC.
Monetising data – prescription drugs
British National Formulary (BNF) codes for prescribed
medicines were recorded in OPCRD. The code identified
a group of drugs rather than a specific brand and dose.
Unit costs for the group at the most disaggregated level
identified were taken from the Northern Ireland
Prescription Cost Analysis (PCA) [14]; the mean and
median of the unit costs in the relevant section of PCA
were then applied to the code resulting in two prescrip-
tion cost scenarios. Where there was evident uncertainty
as to the unit cost applied (based on the coefficient of
variation in unit costs for the group of drugs) or where
the drug was frequently prescribed and misallocation
could have a material effect on results (>200 cases were
observed to be prescribed), a manual exercise was
undertaken linking individual drugs to the PCA.
A confirmatory analysis was subsequently undertaken
in which 50 patients per cohort had drug costs estimated
as described above. All drug costs for these patients
were also manually costed based on the string descrip-
tors for their prescriptions and results compared. One
patient exhibited very high prescription costs and upon
further investigation it was found that they did not have
any prescription quantities present and was therefore
entirely imputed. This individual was deemed an outlier
and excluded from further analysis.
Further details of the costing of the data, outlier inves-
tigation and validation analyses undertaken are available
in the Additional file 1.
Data analysis
Differences in cost between groups differentiated by
corticosteroid exposure may not accurately describe
corticosteroid-induced morbidity costs. Thus, as differ-
ent patterns of morbidity unrelated to corticosteroid ex-
posure may exist between groups it is important to
disentangle morbidity related to corticosteroids and
morbidity that is unrelated. To do this we used a two
stage regression analysis analogous to that of McGregor
et al. [15] and Doherty et al. [16].
In the first stage the relationship between corticoster-
oid exposure and morbidity was determined using a
zero-inflated Poisson model to account for individuals
without any comorbidity (22% of the sample). Here the
number of comorbidities (as identified in Table 1 and
[17]) experienced by an individual was regressed on co-
hort, gender, age group and region, with just cohort
membership in the zero-inflated model to predict the
likelihood of having one or more comorbidities. Age
group was partitioned using an approximate quartile
split of the sample (<46 years, 45–60, 61–70, >70). The
model allowed us to predict the number of additional
morbidities individuals would expect to experience as
their corticosteroid exposure (as defined by cohort
membership) increased. The residual of this regression –
the number of morbidities unexplained by differences in
corticosteroid exposure – provides an estimate of mor-
bidity unrelated to corticosteroid exposure, what might
be considered as background morbidity.
In the second stage a generalised linear model (GLM)
with power link function of 0.5 and Poisson distribution
demonstrated best fit for this right skewed cost data and
was used to examine the relationship between non-
asthma drug costs and corticosteroid exposure (as cap-
tured by cohort membership). The same covariates from
the Poisson model above were used, along with the re-
sidual from the first stage regression (morbidity unre-
lated to corticosteroid exposure) and an interaction term
between age group and cohort membership.
This model explores the relationship between non-
asthma drug costs and corticosteroid exposure control-
ling for differences in background morbidity (i.e. mor-
bidity unrelated to corticosteroid exposure). The
regression focused on non-asthma drug costs, that is the
median overall drug cost (the lower of the two prescrip-
tion cost scenarios described above) minus the median
cost of asthma drugs per patient, as this is a category of
cost we can be certain is not directly asthma related and
for which we can be as certain as possible we are exam-
ining induced as opposed to direct asthma morbidity. By
contrast with GP consultations, for example, while a
consultation may relate to a diabetes clinic, unless the
consultation were actually recorded there is no way of
knowing definitively whether asthma was not discussed
or advice given as part of the consultation and whether
therefore there were not elements of direct as well as in-
duced morbidity.
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Differences in cost based on the regression analyses
were calculated across a range of variables to highlight
differences between specific groups. Sensitivity analyses
examined the impact on estimates of high and low cost
scenarios arising from uncertainty related to the attribu-
tion of activity and to the level of unit cost assigned to
that activity. Analyses were performed using Stata 14.
Results
Demographics for all patients and associated systemic
corticosteroid comorbidities have been described before
[9] and are presented in Table 1 below differentiated by
group.
Confirmatory analyses related to the validation of ac-
tivity costs are reported in detail in Additional file 1 but
in summary resulted in a correlation coefficient between
manually costed data and algorithm costed data of
greater than 0.97 and as such the costing methodology
was deemed acceptable.
Costs per patient in Table 2 are presented on a per
year basis, i.e. the average over the two years. Results
from an analysis of variance (F-test) demonstrated statis-
tically significant differences in both sets of costs across
cohorts (p < 0.01). Costs increase as corticosteroid ex-
posure increases, with drug costs accounting for a
greater proportion of overall costs as this occurs (Fig. 1).
Results from the first stage regression showed a statis-
tically significant and positive relationship between the
level of corticosteroid exposure (evidenced by cohort
membership) and the number of comorbidities; further
Table 1 Demographic, comorbidity and corticosteroid exposure details across cohorts
Demographics All
(n = 7195)
Non-asthma controls
(n = 2412)
Mild/Moderate asthma
(n = 3975)
Severe asthma
(n = 808)
p-value†
Female, n (%) 4503 (63) 1481 (61) 2515 (63) 507 (63) 0.33
Age (years)a 58 ± 17 58 ± 17 58 ± 16 59 ± 17 0.65
Geographical region, n (%)
London 597 (8) 198 (8) 344 (9) 55 (7) 0.22
South of England 903 (13) 333 (14) 477 (12) 93 (12) 0.07
East of England 1064 (15) 333 (14) 616 (16) 115 (14) 0.16
Midlands 2146 (30) 685 (28) 1213 (31) 248 (31) 0.17
North of England 1648 (23) 581 (24) 874 (22) 193 (24) 0.12
Scotland/NI/Wales/unknown 837 (12) 282 (12) 451 (11) 104 (13) 0.47
Number of corticosteroid-related comorbidities, n (%)
Type II diabetes 512 (7) 149 (6) 281 (7) 82 (10) 0.0007
Obesity (Body Mass Index >30) 2285 (32) 561 (23) 1385 (35) 339 (42) <0.0001
Osteopenia 204 (3) 41 (2) 85 (2) 78 (10) <0.0001
Osteoporosis 362 (5) 74 (3) 162 (4) 126 (16) <0.0001
Fracture 263 (4) 88 (4) 134 (3) 41 (5) 0.06
Dyspeptic disorders 3342 (46) 851 (35) 1874 (47) 617 (76) <0.0001
Glaucoma 236 (3) 67 (3) 137 (3) 32 (4) 0.10
Cataract 370 (5) 105 (4) 195 (5) 70 (9) <0.0001
Cardiovascular disease 522 (7) 168 (7) 277 (7) 77 (10) 0.03
Hypertension 2017 (28) 596 (25) 1145 (29) 276 (34) <0.0001
Psychiatric conditions 2155 (30) 607 (25) 1238 (31) 310 (38) <0.0001
Hypercholesterolemia 943 (13) 258 (10) 561 (14) 124 (15) <0.0001
Sleep disorder 172 (2) 40 (2) 99 (3) 33 (4) 0.0003
Chronic kidney disease 619 (9) 167 (7) 342 (9) 110 (14) <0.0001
Inhaled Corticosteroid Dose in Beclomethasone
Diproprionate (BDP) equivalentsa
—— —— 499 ± 323 (n = 3898) 1411 ± 846 (n = 738) <0.0001
OCS Prescriptions per yeara —— —— 1.2 ± 1.8 (n = 995) 11 ± 9 (n = 808) <0.0001
Mean values of inhaled and oral corticosteroids relates only to those with corticosteroid exposure
†P-value’s relate to an analysis of variance between samples (F-test) where three or more samples are being tested, otherwise the equality of means (t-test)
was used
aMean ± Standard Deviation (SD)
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details can be found in the Additional file 1. Second
stage regression analysis identified that, when holding
confounders at their mean levels (to reduce the impact
of extreme values), there is a statistically significant in-
crease in annual non-asthma drugs costs per patient as-
sociated with corticosteroid grouping. Fig. 2 presents the
adjusted cost differences across age groups, where it can
be seen that there is a decreasing pattern in cost differ-
ences related to age.
Table 3 presents estimated corticosteroid-induced
morbidity non-asthma drug costs differentiated by males
and females, as well as males and females combined per
year, arising from the regression analyses. Holding other
covariates at the sample mean, females with high cor-
ticosteroid exposure (severe asthma) would cost ap-
proximately £789 more per year on average than a
corresponding female with no exposure (non-asthma).
The average male from the sample with high exposure
would cost approximately £744 more per year than a
corresponding male with no exposure.
Discussion
The data in this manuscript provides estimates of the add-
itional cost of non-asthma related prescribed medicines
associated with corticosteroid-induced morbidity. The
data demonstrates how much more SA costs relative to
those with moderate or no asthma and how much of this
is as a result of morbidity induced by corticosteroid expos-
ure. The corticosteroid-induced prescription costs are on
average approximately £112 more for those in the moder-
ate exposure group and £772 for those in the high expos-
ure group. If we assume a similar pattern in respect of
clinical activity as for prescriptions, then 51% of the differ-
ence in clinical activity costs can be attributed to
corticosteroid-induced morbidity for the SA group and
39% for the moderate asthma group. The average activity
costs (across the 6 scenarios described above) associated
with corticosteroid-induced morbidity would therefore be
£538 and £112, respectively. The estimated annual cost of
corticosteroid-induced morbidity, for prescription drugs
and healthcare activity combined, would amount to £1310
(£772 plus £538) for the high exposed group and £224
(£112 plus £112) for the low exposure group.
Table 2 Mean annual costs per patient for highest and lowest cost scenarios across cohorts
Non-asthma (n = 2411) Mild/Moderate asthma (n = 3975) Severe asthma (n = 808)
Low High Low High Low High
Clinical activitya £ 350 ± 546 £ 1111 ± 2372 £ 491 ± 630 £ 1579 ± 2902 £ 911 ± 907 £ 2799 ± 3705
Prescription drugsa £ 210 ± 790 £ 212 ± 700 £ 487 ± 957 £ 493 ± 947 £ 1692 ± 2369 £ 1734 ± 2346
Total cost £ 560 £ 1324 £ 978 £ 2072 £ 2603 £ 4533
Six scenarios were created for clinical costs to capture uncertainty around the likely consultation to be costed (2 scenarios) and median, and IQ ranges (3 scenarios)
aMean ± SD
Fig. 1 Mean annual healthcare activity and prescription drugs costs.
Mean annual healthcare costs by service group across cohorts (For a
full list of activities grouped under each service, see Additional file 1:
Table S4), along with asthma related and non-asthma related
prescription drug costs. Costs are calculated as the average across
High-Low cost scenarios; bar height represents the average of this
annual cost per patient per group. ‘Other’ includes physiotherapists,
psychiatrists, and opticians, among others and accounted for such a
small proportion of total healthcare costs that it cannot be seen on
the graph
Fig. 2 Adjusted differences, between OCS exposure groups, in
annual non-asthma prescription costs per patient across age-groups.
Difference in annual non-asthma drug cost per patient at each age-
group between those with high OCS exposure and those without
OCS exposure (red) and between those with low OCS exposure and
those without OCS exposure (blue). Differences in costs per patient
are adjusted for confounders (sex, region and background morbidity)
and calculated holding confounders at the sample mean. Outer lines
represent 95% confidence intervals around these estimates
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Differences in morbidity costs, even after controlling
for morbidity unrelated to corticosteroids and other con-
founders (region), are higher among women than men
and among younger age groups (although confidence in-
tervals overlap – Fig. 2). Essentially the data demon-
strates that differences in cost between those with high
exposure to OCS and those with no exposure are lower
in older age groups. Although research on this age-
related cost differential topic is sparse, this effect has
been noted elsewhere [18].
This may have important implications specific to the
management of asthma. While differences in cost related
to gender are unlikely to materially affect evaluations of
corticosteroid-sparing therapies, differences related to
age could point to possible differences in the cost-
effectiveness of corticosteroid-sparing therapies related
to age with greater cost-effectiveness in younger pa-
tients. We acknowledge that our analysis is cross sec-
tional by design and longitudinal data on corticosteroid
exposure and morbidity would better help to understand
the relationship between corticosteroid exposure, cost
and age.
Severe asthmatics were defined in this study in part by
their consumption of ≥4 prescriptions for OCS. Such pa-
tients meet the current United Kingdom National
Institute for Clinical and Healthcare Excellence criteria
to access both omalizumab and mepolizumab (biologic
therapies which have some systemic steroid sparing ac-
tivity) [19]. As noted, our estimates of the cost of
corticosteroid-induced morbidity are therefore poten-
tially pertinent to the estimated cost-effectiveness of
such therapies. While estimating the cost-effectiveness
of corticosteroid-sparing therapies is beyond the scope
of this paper, the inclusion of potential savings related to
corticosteroid-induced morbidity estimated in this study
would serve to improve the estimated cost-effectiveness
of such therapies.
Lefebvre et al’s US based study 2016 [18] found that a
high-dose systemic corticosteroid (SCS) (>12 mg/day)
group would cost approximately £5,949 more in terms
of both drugs and activity, per year than a non-SCS ex-
posure group (data was published in 2013 US Dollars
and have been converted into 2013 Great British Pounds
(GBP), adjusting for purchasing power parity [20]).
These estimates are somewhat higher than those pro-
duced here, though it is difficult to make direct compari-
sons between the two studies given differences in study
settings, healthcare systems under which patients health-
care costs are incurred (the US has higher healthcare
costs [21]), and different costing methodologies. The
data used by Lefebvre et al. are confined to a selected set
of US states and to Medicaid recipients within those
states, which may also influence estimate of induced
morbidity costs. For example, Medicaid recipients may
exhibit poorer general health, different patterns of ser-
vice use and outcomes, both among those with cortico-
steroid exposure and between those with and without
such exposure. Whether the estimates are generalisable
is therefore unclear. It is also noted that the authors’
measure differences in resource use relative to a group
without corticosteroid exposure which are not matched
by age and consequently the mean age of the exposure
group (57.6 years) is more than twice the mean age of
the group without exposure (27.4 years), which may also
make inference from these results less reliable. A
strength of our data is that we are able to estimate costs
unrelated to asthma among a nationally representative
group of patients including a control group, matched by
age, gender and year of birth, without corticosteroid
exposure.
Our study does have limitations. Firstly, the large data-
set required the estimation of costs, described above,
which in turn required some assumptions and clinical
judgement. However steps were taken to reduce errors
in estimation and possible biases that may have arisen in
our approach; based on the confirmatory and sensitivity
analyses (see supplement), we do not expect that the
data would be biased in a systematic way.
Secondly, the first stage regression investigates the ef-
fect of corticosteroid exposure on the number of comor-
bidities in order to identify the impact on comorbidity
which is potentially unrelated to corticosteroid exposure
(the residual from this equation). Because the number of
comorbidities is used, rather than each comorbidity and
its specific severity separately, they are given equal
weighting. This may lead to increased variance in the
costing estimates provided. Weights to account for dif-
ference in severity of conditions, such as the Charlson
comorbidity index [22] were considered however differ-
ences in our data and the data required to calculate the
index would require many additional assumptions. This
could therefore be less reliable than our current esti-
mates and was not considered a worthwhile exercise in
this case.
Table 3 Adjusted difference in non-asthma drug costs per
patient per year relative to control group
Base: No OCS exposure
(Non-asthma control)
Adjusted cost
differences
Lower bound
CI (95%)
Upper bound
CI (95%)
Low OCS exposure
(Mild/Moderate asthma)
Female £ 115a £ 82 £ 148
Male £ 106a £ 77 £ 135
Total £ 112a £ 80 £ 143
High OCS exposure
(Severe asthma)
Female £ 789a £ 652 £ 927
Male £ 744a £ 620 £ 868
Total £ 772a £ 641 £ 903
Data are presented for males, females and with gender at the sample
mean (total)
aSignificant at α = 0.01
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Thirdly, the estimates in this manuscript focus on
non-asthma prescription drug costs where the opportun-
ity to disentangle morbidity and induced morbidity costs
is more straightforward. Separating healthcare activity
costs due to asthma from healthcare activity due other
morbidities is not straightforward. Estimates of increased
healthcare activity associated with asthma related co-
morbidity were attempted in a Canadian study but cost
estimates were not provided [23]. While extrapolations
to other healthcare activity are offered here these are for
illustrative purposes, a prospective and more detailed
examination of the impact of corticosteroid exposure on
ambulatory and hospital care costs remains a subject for
further research.
Conclusion
This paper estimates the additional cost of non-asthma
related prescribed medicines and healthcare activity as-
sociated with corticosteroid-induced morbidity in severe
asthma. Corticosteroid-induced morbidity costs are
higher among women than men and among younger pa-
tients suggesting that younger age groups facing a
greater economic burden of corticosteroid related co-
morbidity relative to older age groups. The potential sav-
ings associated with corticosteroid-induced morbidity
which would be avoided through use of effective
corticosteroid-sparing treatments should be incorpo-
rated in models which estimate the cost-effectiveness of
such therapies. These savings are important in consider-
ations of the relative value for money of such therapies
and in decisions around which groups should be
afforded access to such therapies.
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